Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of full-oral metronomic vinorelbine + capecitabine in advanced or metastatic breast cancer
2010-023794-19Phase 2Completed
- Sponsor
- Fondazione IRCCS San Gerardo dei Tintori
- Start
- Dec 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and capecitabine in breast cancer and breast adenocarcinoma, sponsored by Fondazione IRCCS San Gerardo dei Tintori. Primary endpoint: Clinical benefit at 24 weeks. Started Dec 2011; status: completed.
02
Drugs
vinorelbinecapecitabine
03
Conditions
breast cancerbreast adenocarcinoma
Beyond the preview
Go deeper on 2010-023794-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023794-19.